- Home
- VSTS vs KROS Comparison
VSTS vs KROS Comparison
Compare VSTS & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTS
- KROS
- Stock Information
- Founded
- VSTS 1936
- KROS 2015
- Country
- VSTS United States
- KROS United States
- Employees
- VSTS N/A
- KROS N/A
- Industry
- VSTS
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- VSTS
- KROS Health Care
- Exchange
- VSTS Nasdaq
- KROS Nasdaq
- Market Cap
- VSTS 2.2B
- KROS 633.5M
- IPO Year
- VSTS N/A
- KROS 2020
- Fundamental
- Price
- VSTS $15.32
- KROS $15.92
- Analyst Decision
- VSTS Hold
- KROS Buy
- Analyst Count
- VSTS 6
- KROS 11
- Target Price
- VSTS $15.73
- KROS $68.83
- AVG Volume (30 Days)
- VSTS 2.6M
- KROS 1.9M
- Earning Date
- VSTS 02-05-2025
- KROS 02-26-2025
- Dividend Yield
- VSTS 0.92%
- KROS N/A
- EPS Growth
- VSTS N/A
- KROS N/A
- EPS
- VSTS 0.16
- KROS N/A
- Revenue
- VSTS $2,805,820,000.00
- KROS $651,000.00
- Revenue This Year
- VSTS $2.82
- KROS $224.66
- Revenue Next Year
- VSTS $2.98
- KROS N/A
- P/E Ratio
- VSTS $95.51
- KROS N/A
- Revenue Growth
- VSTS N/A
- KROS 8037.50
- 52 Week Low
- VSTS $8.92
- KROS $15.33
- 52 Week High
- VSTS $22.37
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- VSTS 44.70
- KROS 22.66
- Support Level
- VSTS $14.96
- KROS $15.33
- Resistance Level
- VSTS $15.43
- KROS $17.25
- Average True Range (ATR)
- VSTS 0.43
- KROS 1.37
- MACD
- VSTS -0.16
- KROS -0.48
- Stochastic Oscillator
- VSTS 21.05
- KROS 10.31
About VSTS Vestis Corporation
Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.